Prior authorization & UM · Lab / specialty PA + transparency
Careviso
Careviso builds seeQer for prior authorization, eligibility, and financial transparency, with a long lab and specialty-provider footprint. It is not a payer clinical UM determination console.
Strong fit
- Labs and specialty groups drowning in medical-benefit prior auth volume
- Access teams that also need eligibility, cost estimates, and PA submission routing in one workflow
- Buyers measuring days-to-authorization and enrollment coverage across a large ordering network
Weak fit
- Payers building an internal clinical UM determination suite
- Clinics with almost no prior-auth load that only need a fax cover sheet
- Buyers who will not change how staff handle exceptions after automated submissions
Bottom line
Careviso earns a Recommend for lab and specialty access teams whose prior authorization work still stalls on portal hunting and incomplete submissions. Outcomes show up in faster authorization turnaround and fewer abandoned orders when seeQer owns eligibility, cost estimates, and PA routing together. Product strength is specialty and lab PA plus financial transparency rather than a full payer UM console like Agadia or Xsolis. Implementation needs a named access owner and clean order feeds. Pricing is quote-based. Third-party revenue estimates commonly sit near $6M to $29M, under the hard cap. Score sits with Agadia on overall for a different, provider-and-lab shaped problem, above Silna and SamaCare on this board.
Score breakdown
Weights: Outcomes 35% · Product 30% · Implementation 20% · Pricing clarity 15%.
Careviso builds seeQer, a patient-access platform that automates prior authorizations, benefit checks, and cost estimates for labs, specialty providers, and ordering networks. Company materials cite hundreds of thousands of enrolled providers and growing PA volume.
It is not a payer utilization-management determination suite. Compare Silna or SamaCare when specialty clinics need care-readiness ops, Infinitus when phone-based payor follow-up is the bottleneck, and Hindsait when the buyer is a plan needing clinical NLP on the review side.
Score reflects strong access outcomes for lab and specialty PA with less fit for full UM policy engines.
Competitor landscape
| Vendor | Overall | Ease of implementation |
|---|---|---|
| Careviso | 7.6 | 7.3 |
| Infinitus | 7.7 | 7.4 |
| Silna Health | 7.3 | 7.1 |
| SamaCare | 7.1 | 7.0 |
| Hindsait | 7.0 | 6.7 |
| Valer | 6.6 | 6.4 |
| Linear Health | 6.5 | 7.0 |
Pricing
| Item | Detail |
|---|---|
| Model | Platform packaging for prior authorization, eligibility, and financial transparency; quote-based. |
| What usually drives cost | Authorization volume, provider network size, seeQer modules (PA, cost estimates, pharmacy benefit), and support tier. |
| What to ask in diligence | All-in platform cost at your monthly PA and estimate volume, with enrollment and exception coverage defined. |
| Published pricing | Public list price: not published. Expect volume-based platform pricing. |
Prerequisites for purchase
| Need | Why it matters |
|---|---|
| What you need to get Careviso to function | |
| Named prior-auth or access owner with authority to change submission workflows | Software without owners becomes shelfware. |
| Baseline authorization turnaround and denial or abandonment rates captured | You cannot prove value without a before number. |
| EHR, ordering, or practice-management feed inventory documented | Missing feeds recreate portal swivel-chair work. |
| Staffing plan for exception queues after go-live | Unowned exceptions age into delayed care. |
| Top payers and service lines by PA volume listed | Generic configs miss your real bottlenecks. |
| What will maximize your value | |
| Track median days-to-authorization weekly for 90 days | Login counts are not outcomes. |
| Start with one specialty or lab channel first | Narrow wins beat empty enterprise banners. |
| Retire duplicate spreadsheet trackers after a parallel month | Dual entry doubles cost. |
| Review stalled exceptions in a standing huddle | Silent aging hides failure. |
| Publish a monthly access digest to clinical and revenue leaders | Hidden delays surprise everyone. |
| Deal-breakers | |
| Nobody will own prior-auth exception queues. | |
| You refuse the interface or enrollment work the product needs. | |
| You expect a full EHR replacement from a PA tool. | |
| Leadership will not measure authorization turnaround. | |
| Compliance blocks the data path required for submissions. | |
Value creation time frame
| # | Stage | Typical range |
|---|---|---|
| 1 | Scope & baseline | 2-4 weeks - Metrics, payer mix, feed inventory. |
| 2 | Configure | 4-10 weeks - Rules, templates, interfaces; test cases. |
| 3 | Pilot | 2-6 weeks - One specialty or site; exception playbook. |
| 4 | Scale | 1-3 months - Add payers/sites; retire shadow trackers. |
Methodology
| Weight | Factor | What it measures |
|---|---|---|
| 35% | Customer outcomes | Whether buyers get measurable operational or clinical-workflow results after go-live |
| 30% | Product | Capability depth, reliability, and fit for the job the category actually buys |
| 20% | Implementation | How hard it is to stand up, integrate, train, and stabilize |
| 15% | Pricing clarity | Whether a buyer can model total cost without a mystery quote |
| Label | Meaning |
|---|---|
| Highly recommend | Strong outcomes and product with manageable caveats |
| Recommend | Solid fit for the right buyer; know the tradeoffs |
| Conditional | Only with a specific use case or heavy caveats |
| Not recommended | Avoid for most buyers in this category |
Read our full methodology for how we weight scores and assign recommend labels.